61 (discordance in direction and statistical significance) Bose ADDIN EN.CITE Patients with CKD or Placebo/no End-stage kidney 2014 Allopurinol 2 164 NA RR Random 1.01 (0.15, 6.98) decreased kidney treatment disease function Zhang ADDIN EN.CITE Placebo/no Blood urea nitrogen -6.15 (-8.17, 2014 CKD Patients Allopurinol 3 169 83 MD Fixed treatment (mmol/L) Zhang ADDIN EN.CITE Placebo/no 24-h urinary 2014 CKD Patients Allopurinol 3 184 94 MD Fixed 0.13 (0.28, 0.02) treatment protein (g/day) Zhang ADDIN EN.CITE Placebo/no 2014 CKD Patients Allopurinol Stable renal function 5 267 132 RR Fixed 1.73 (1.44, 2.09) treatment
61 (discordance in direction and statistical significance) Bose ADDIN EN.CITE 2014 Patients with CKD or decreased kidney function Allopurinol Placebo/no treatment End-stage kidney disease 2 164 NA RR Random 1.01 (0.15, 6.98) Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment Blood urea nitrogen (mmol/L) 3 169 83 MD Fixed -6.15 (-8.17, Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment 24-h urinary protein (g/day) 3 184 94 MD Fixed 0.13 (0.28, 0.02) Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment Stable renal function 5 267 132 RR Fixed 1.73 (1.44, 2.09)
Supplementary%20material_v7%20-%20Final-2.docx